The production of anti-MDA5 antibodies is strongly associated with DM, especially with CADM, and rapidly progressive ILD (RP-ILD), and this subset is associated with particularly poor clinical outcomes [3–11]. Here, IFIH1 is linked to interstitial lung disease.